Patency Trials With Reteplase (r-PA): What Do They Tell Us?
Identifieur interne : 001107 ( Main/Exploration ); précédent : 001106; suivant : 001108Patency Trials With Reteplase (r-PA): What Do They Tell Us?
Auteurs : Christoph Bode [Allemagne] ; Thomas K. Nordt [Allemagne] ; Karlheinz Peter [Allemagne] ; Richard W. Smalling [États-Unis] ; Marschall S. Runge [États-Unis] ; Wolfgang Kübler [Allemagne]Source :
- The American Journal of Cardiology [ 0002-9149 ] ; 1996.
Abstract
Thrombolytic therapy has been shown to reduce mortality and morbidity after acute myocardial infarction. Therapeutic benefit seems to be directly correlated with completeness of reperfusion (Thrombolysis in Myocardial Infarction [TIMI] grade 3 flow) of the infarct-related coronary artery, as well as the timeliness of reperfusion. To determine which regimen of reteplase (r-PA), a deletion mutant of wild-type tissue plasminogen activator (t-PA), is most effective for clinical thrombolysis, several reteplase regimens were compared with the most successful standard regimens of recombinant t-PA (alteplase) in 2 large-scale, randomized studies. All patients received aspirin and intravenous heparin. In the Reteplase Angiographic Phase II International Dose Finding Trial (RAPID-1), results in 606 randomized patients showed that a 10 + 10 U double bolus of reteplase was more effective than a 15 U single bolus, a 10 + 5 double bolus, or conventional alteplase (100 mg over 3 hours). In the Reteplase versus Alteplase Patency Investigation During Acute Myocardial Infarction (RAPID-2) trial, results in 324 patients showed that significantly more patients achieved patency of the infarct-related artery (TIMI grade 2 or 3 flow) at 90 minutes with reteplase (10 + 10 U double bolus) than with accelerated alteplase (100 mg over 90 minutes): 83.4% versus 73.3%, respectively (p = 0.03). The incidence of complete patency (TIMI grade 3 flow) at 90 minutes was likewise greater with reteplase than with accelerated alteplase (59.9% vs 45.2%, respectively; p = 0.01). At 60 minutes, the incidence of TIMI grade 2 or 3 flow was also significantly higher with reteplase than with alteplase (81.8% vs 66.1%, respectively; p = 0.01), as was the incidence of TIMI grade 3 flow (51.2% vs 37.4%, respectively; p <0.031). The 35-day mortality rate was 4.1% for reteplase and 8.4% for alteplase (p = not significant). Reteplase and alteplase did not differ significantly with regard to the occurrence of severe bleeding (12.4% vs 9.7%, respectively) or hemorrhagic stroke (1.2% vs 1.9%, respectively). The results of these trials show that reteplase, given as a 10 + 10 U double bolus, achieves significantly higher rates of early reperfusion of the infarct-related coronary artery and is associated with significantly fewer acute coronary interventions when compared with front-loaded alteplase. The benefits of reteplase are achieved without any apparent increased risk of complications. © 1996 by Excerpta Medica, Inc. Am J Cardiol 1996;78(suppl 12A):16–19
Url:
DOI: 10.1016/S0002-9149(96)00738-2
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001440
- to stream Istex, to step Curation: 001440
- to stream Istex, to step Checkpoint: 000C55
- to stream Main, to step Merge: 001173
- to stream Main, to step Curation: 001107
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Patency Trials With Reteplase (r-PA): What Do They Tell Us?</title>
<author><name sortKey="Bode, Christoph" sort="Bode, Christoph" uniqKey="Bode C" first="Christoph" last="Bode">Christoph Bode</name>
</author>
<author><name sortKey="Nordt, Thomas K" sort="Nordt, Thomas K" uniqKey="Nordt T" first="Thomas K" last="Nordt">Thomas K. Nordt</name>
</author>
<author><name sortKey="Peter, Karlheinz" sort="Peter, Karlheinz" uniqKey="Peter K" first="Karlheinz" last="Peter">Karlheinz Peter</name>
</author>
<author><name sortKey="Smalling, Richard W" sort="Smalling, Richard W" uniqKey="Smalling R" first="Richard W" last="Smalling">Richard W. Smalling</name>
</author>
<author><name sortKey="Runge, Marschall S" sort="Runge, Marschall S" uniqKey="Runge M" first="Marschall S" last="Runge">Marschall S. Runge</name>
</author>
<author><name sortKey="Kubler, Wolfgang" sort="Kubler, Wolfgang" uniqKey="Kubler W" first="Wolfgang" last="Kübler">Wolfgang Kübler</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E342E2AB08BD215E4D1C7D2BC677E185BE02E587</idno>
<date when="1996" year="1996">1996</date>
<idno type="doi">10.1016/S0002-9149(96)00738-2</idno>
<idno type="url">https://api.istex.fr/document/E342E2AB08BD215E4D1C7D2BC677E185BE02E587/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001440</idno>
<idno type="wicri:Area/Istex/Curation">001440</idno>
<idno type="wicri:Area/Istex/Checkpoint">000C55</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C55</idno>
<idno type="wicri:doubleKey">0002-9149:1996:Bode C:patency:trials:with</idno>
<idno type="wicri:Area/Main/Merge">001173</idno>
<idno type="wicri:Area/Main/Curation">001107</idno>
<idno type="wicri:Area/Main/Exploration">001107</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Patency Trials With Reteplase (r-PA): What Do They Tell Us?</title>
<author><name sortKey="Bode, Christoph" sort="Bode, Christoph" uniqKey="Bode C" first="Christoph" last="Bode">Christoph Bode</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Medizinische Klinik III (Kardiologie, Angiologie und Pulmonologie, Universität Heidelberg, Heidelberg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nordt, Thomas K" sort="Nordt, Thomas K" uniqKey="Nordt T" first="Thomas K" last="Nordt">Thomas K. Nordt</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Medizinische Klinik III (Kardiologie, Angiologie und Pulmonologie, Universität Heidelberg, Heidelberg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peter, Karlheinz" sort="Peter, Karlheinz" uniqKey="Peter K" first="Karlheinz" last="Peter">Karlheinz Peter</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Medizinische Klinik III (Kardiologie, Angiologie und Pulmonologie, Universität Heidelberg, Heidelberg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smalling, Richard W" sort="Smalling, Richard W" uniqKey="Smalling R" first="Richard W" last="Smalling">Richard W. Smalling</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cardiology, University of Texas Medical School at Houston, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Runge, Marschall S" sort="Runge, Marschall S" uniqKey="Runge M" first="Marschall S" last="Runge">Marschall S. Runge</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cardiology, University of Texas Medical Branch at Galveston, Galveston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kubler, Wolfgang" sort="Kubler, Wolfgang" uniqKey="Kubler W" first="Wolfgang" last="Kübler">Wolfgang Kübler</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Medizinische Klinik III (Kardiologie, Angiologie und Pulmonologie, Universität Heidelberg, Heidelberg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">The American Journal of Cardiology</title>
<title level="j" type="abbrev">AJC</title>
<idno type="ISSN">0002-9149</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1996">1996</date>
<biblScope unit="volume">78</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="supplement">S1</biblScope>
<biblScope unit="page" from="16">16</biblScope>
<biblScope unit="page" to="19">19</biblScope>
</imprint>
<idno type="ISSN">0002-9149</idno>
</series>
<idno type="istex">E342E2AB08BD215E4D1C7D2BC677E185BE02E587</idno>
<idno type="DOI">10.1016/S0002-9149(96)00738-2</idno>
<idno type="PII">S0002-9149(96)00738-2</idno>
<idno type="ArticleID">96007382</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0002-9149</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Thrombolytic therapy has been shown to reduce mortality and morbidity after acute myocardial infarction. Therapeutic benefit seems to be directly correlated with completeness of reperfusion (Thrombolysis in Myocardial Infarction [TIMI] grade 3 flow) of the infarct-related coronary artery, as well as the timeliness of reperfusion. To determine which regimen of reteplase (r-PA), a deletion mutant of wild-type tissue plasminogen activator (t-PA), is most effective for clinical thrombolysis, several reteplase regimens were compared with the most successful standard regimens of recombinant t-PA (alteplase) in 2 large-scale, randomized studies. All patients received aspirin and intravenous heparin. In the Reteplase Angiographic Phase II International Dose Finding Trial (RAPID-1), results in 606 randomized patients showed that a 10 + 10 U double bolus of reteplase was more effective than a 15 U single bolus, a 10 + 5 double bolus, or conventional alteplase (100 mg over 3 hours). In the Reteplase versus Alteplase Patency Investigation During Acute Myocardial Infarction (RAPID-2) trial, results in 324 patients showed that significantly more patients achieved patency of the infarct-related artery (TIMI grade 2 or 3 flow) at 90 minutes with reteplase (10 + 10 U double bolus) than with accelerated alteplase (100 mg over 90 minutes): 83.4% versus 73.3%, respectively (p = 0.03). The incidence of complete patency (TIMI grade 3 flow) at 90 minutes was likewise greater with reteplase than with accelerated alteplase (59.9% vs 45.2%, respectively; p = 0.01). At 60 minutes, the incidence of TIMI grade 2 or 3 flow was also significantly higher with reteplase than with alteplase (81.8% vs 66.1%, respectively; p = 0.01), as was the incidence of TIMI grade 3 flow (51.2% vs 37.4%, respectively; p <0.031). The 35-day mortality rate was 4.1% for reteplase and 8.4% for alteplase (p = not significant). Reteplase and alteplase did not differ significantly with regard to the occurrence of severe bleeding (12.4% vs 9.7%, respectively) or hemorrhagic stroke (1.2% vs 1.9%, respectively). The results of these trials show that reteplase, given as a 10 + 10 U double bolus, achieves significantly higher rates of early reperfusion of the infarct-related coronary artery and is associated with significantly fewer acute coronary interventions when compared with front-loaded alteplase. The benefits of reteplase are achieved without any apparent increased risk of complications. © 1996 by Excerpta Medica, Inc. Am J Cardiol 1996;78(suppl 12A):16–19</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>États-Unis</li>
</country>
<region><li>Bade-Wurtemberg</li>
<li>District de Karlsruhe</li>
<li>Texas</li>
</region>
<settlement><li>Heidelberg</li>
</settlement>
</list>
<tree><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Bode, Christoph" sort="Bode, Christoph" uniqKey="Bode C" first="Christoph" last="Bode">Christoph Bode</name>
</region>
<name sortKey="Kubler, Wolfgang" sort="Kubler, Wolfgang" uniqKey="Kubler W" first="Wolfgang" last="Kübler">Wolfgang Kübler</name>
<name sortKey="Nordt, Thomas K" sort="Nordt, Thomas K" uniqKey="Nordt T" first="Thomas K" last="Nordt">Thomas K. Nordt</name>
<name sortKey="Peter, Karlheinz" sort="Peter, Karlheinz" uniqKey="Peter K" first="Karlheinz" last="Peter">Karlheinz Peter</name>
</country>
<country name="États-Unis"><region name="Texas"><name sortKey="Smalling, Richard W" sort="Smalling, Richard W" uniqKey="Smalling R" first="Richard W" last="Smalling">Richard W. Smalling</name>
</region>
<name sortKey="Runge, Marschall S" sort="Runge, Marschall S" uniqKey="Runge M" first="Marschall S" last="Runge">Marschall S. Runge</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Eau/explor/LotaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001107 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001107 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Eau |area= LotaV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:E342E2AB08BD215E4D1C7D2BC677E185BE02E587 |texte= Patency Trials With Reteplase (r-PA): What Do They Tell Us? }}
This area was generated with Dilib version V0.6.39. |